Skip to main content

Table 2 CMR and MRS findings

From: Impaired energetics and normal myocardial lipids in rheumatoid arthritis and systemic lupus erythematosus: a phosphorous and proton magnetic resonance spectroscopy and cardiovascular magnetic resonance study

  Controls N=12 RA N=16 SLE N=13 P value
LVEDV indexed to BSA, ml/m2 78 ± 15 79 ± 23 74 ± 13 0.54
LVESV indexed to BSA, ml/m2 23 ± 5 23 ± 11 21 ± 6 0.75
LVEF, % 72 ± 4 72 ± 7 72 ± 5 0.96
LV Mass indexed to BSA, g/m2 53 ± 14 55 ± 11 47 ± 7 0.09
LA size, mm 27 ± 5 33 ± 6 29± 4 0.02
Mid SA circumferential strain -18.7 ± 1.1 -17.5 ± 0.9 -16.5 ± 0.8 <0.001
Peak diastolic circumferential strain rate (s-1) 118 ± 21 88 ± 18 76 ± 24 <0.001
Presence of LGE (%) 0 8 (50) 3 (23) -
Volume fraction of LGE>2SD (%) 0 3.4 ± 0.4 2.6 ± 0.3 -
Global myocardial T2 SI Ratio 1.5 ± 0.1 1.7 ± 0.3 1.9 ± 0.4 0.03
Volume fraction of oedema by T2 (%) 0 26 (18-39) 20 (13-31) -
Average myocardial T1, ms 961 ± 12 968 ±25 987 ± 26 0.01
Volume fraction of T1>990ms (%) 3 (1-5) 34 (17-55) 41 (23-61) <0.001
ECV (%) 26.5 ± 2.7 30.4 ± 3.1 32.2 ± 4.4 <0.001
MPRI 2.0 ± 0.3 1.6 ± 0.2 1.5 ± 0.5 <0.001
PCr/ATP 2.0 ± 0.3 1.5 ± 0.3 1.4 ± 0.3 <0.001
Cardiac lipid content (%) 0.49 ± 0.37 0.46 ± 0.33 0.58 ± 0.27 0.78
Hepatic lipid content (%) 1.70 ± 0.72 1.46 ± 0.58 2.17 ± 1.02 0.64
  1. Continuous data are mean ± SD unless otherwise indicated. BSA, body surface area; ECV, extracellular volume; LA, left atrium; LGE, late gadolinium enhancement; LV, left ventricle/ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; MPRI, myocardial perfusion reserve index; PCr/ATP, phosphocreatine to adenosine triphosphate ratio; RPP, rate pressure product; SA, short axis; SI, signal intensity, SLE, systemic lupus erythematosus